NewcelX (NCEL) news
Recent news
Newcelx announces pricing of $1.4 million equity financing at 20% premium pricing
AInvest Wire · Jul 31, 2026Newcelx AG - granted Brazilian patent for NCEL-101 manufacturing process until November 2036
Newcelx AG has been granted a patent in Brazil for its NCEL-101 manufacturing process, with protection extending until November 2036 patent expiration . This development follows the company’s ongoing efforts to secure intellectual property rights across key markets. The patent covers proprietary…
AInvest Wire · Jul 15, 2026Newcelx: FDA feedback supports planned development strategy
NewCelX Ltd. (Nasdaq: NCEL) has taken a significant step in its clinical development strategy for NCEL-101, an advanced cell therapy candidate for Type 1 Diabetes, by engaging in a Pre-IND meeting with the U.S. Food and Drug Administration (FDA). The company is working in collaboration with Eledon…
AInvest Wire · Jul 1, 2026Newcelx AG - FDA approves Newcelx to proceed with IND-enabling activities for NCEL-101
AInvest Wire · Jul 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.